FHFei Hong

Fei Hong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fei Hong has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A comprehensive analysis of coagulopathy during anti‐B cell maturation antigen chimeric antigen receptor‐T therapy in multiple myeloma, a retrospective study based on LEGEND‐2

    by Rui Liu, Yang Lv, Fei Hong, Wanhong Zhao, Bo Lei, Jie Liu, Wanggang Zhang, Aili He, Fangxia Wang

    Chimeric antigen receptor (CAR)‐reprogrammed T cell therapy is a novel and powerful treatment against hematological malignancies. Cytokine release syndrome (CRS) and other potentially life‐threatening toxicities are known side effects which need appropriate management and supportive care. Coagulopathy is a common and severe CAR‐T‐related adverse event, while a comprehensive profile of coagulopathy in patients with multiple myeloma (MM) undergoing CAR‐T cell therapy has not been reported. Therefore, we performed a comprehensive analysis of coagulopathy in 51 patients with r/r MM given anti‐B cell maturation antigen CAR‐T cell therapy. We found that 49% of patients had coagulation disorders, and 29% of patients experienced disseminated intravascular coagulation (DIC). Severe CRS, abnormal liver function and higher tumor burden were risk factors for the CAR‐T‐related coagulopathy. We found that the serum IL‐6 level and alanine aminotransferase level were potential indicators for CAR‐T‐related DIC. Furthermore, we found that coagulation disorders occurred within 1 month after CAR‐T cell infusion, mainly between days 10 and 13, which was 2−5 days later than the beginning of CRS and simultaneous with the beginning of abnormal liver function and the peak of CRS. In addition, although patients with coagulation dysfunction had a trend for better outcomes and prognosis, no statistical significance was found. In conclusion, our research provided a comprehensive understanding of CAR‐T‐related coagulopathy in MM. Upon timely and standardized treatment, coagulopathy was manageable in most cases.


  • Open Access

    Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia

    by Fei Hong, Ming Shi, Jiang Cao, Ying Wang, Yanqing Gong, Hui Gao, Zhenyu Li, Junnian Zheng, Lingyu Zeng, Aili He, et al.

    CD19‐target chimeric antigen receptor (CAR)‐T cell therapy is highly effective for relapsed/refractory (R/R) acute lymphoblastic leukaemia (ALL), but is often complicated by cytokine release syndrome (CRS), which is potentially life‐threatening. Endothelial cells are the core regulator of CRS in many infectious diseases and may also play a key role after CAR‐T cell therapy. We provided a detailed clinical, laboratory description and endothelial cell activation biomarkers in patients with CRS. Endothelial cell activation was associated with occurrence, development and severity of CRS, manifested by decreased serum angiopoietin (Ang)‐1 levels and increased levels of von Willebrand Factor (VWF), Ang‐2, Ang‐2:Ang‐1, sE‐selectin, soluble intercellular adhesion molecule (sICAM‐1) and soluble vascular cell adhesion molecule (sVCAM)‐1. Besides, the endothelial activation was correlated with the hepatic, kidney and hematopoietic dysfunction in CRS patients. After infusion of CAR‐T cells, we detected changes of endothelial activation‐related biomarkers within 36 hours in patients who subsequently developed CRS, especially severe CRS. Using top tree models, we could predict which patients would develop CRS, especially severe CRS, or identify the severity of CRS by certain biomarkers of endothelial activation. These data provide a new idea and will help identify new targets for early intervention and prevention of CRS.